Beleave Inc. (CSE: BE; OTCQX: BLEVF) is pleased to announce that its wholly-owned subsidiary, Beleave Kannabis Corp., has received its sales license from Health Canada pursuant to the Access to Cannabis for Medical Purposes Regulations.
“We are thrilled to have obtained our sales license from Health Canada,” stated Beleave CEO, Andrew Wnek. “We have remained diligent and focused throughout the process. We are excited to be able to continue to move the company forward as a result of this news.”
The Company also announces that it has granted 200,000 stock options to purchase common shares to certain members of its board of directors in accordance with the Company’s stock option plan. Each option is exercisable to purchase one common share of the Company at $3.00 per common share. All Options vest immediately and expire on January 3, 2021. All common share and option issuances are subject to applicable regulatory approvals (including the Canadian Securities Exchange).
About Beleave
Beleave Inc. is a biotech company and Beleave’s wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave’s purpose-built facility is located in Hamilton, Ontario.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
